MSD Animal Health, a division of Merck & Co, announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted two additional indications of a marketing authorisation for the veterinary medicinal product Bravecto (fluralaner) Chew and Bravecto Spot-On for dogs.
The new therapeutic indications are for the treatment of demodectic (Demodex canis) mites and sarcoptic (Sarcoptes scabiei var. canis) infestations with Bravecto Chew and Spot-On for dogs. Bravecto Chew and Spot-On are also indicated for protection against flea and tick infestations in dogs, and can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Demodex canis mites, which live in the hair follicles and sebaceous glands in the skin of dogs, can multiply rapidly and cause severe crusting and secondary infections. Infestation causes demodicosis, a skin disease characterised by scabs and infection, hair loss and red skin. A single administration of Bravecto chewable tablets or a single application of Bravecto spot-on solution, both at the currently approved dose is effective for the treatment of demodicosis caused by Demodex canis in dogs.
Sarcoptes scabiei var. canis mites burrow into the top layer of a dog’s skin, causing intense itching that can lead to skin infections. Infestation is called scabies mange and is a highly contagious skin disease characterised by hair loss, skin irritation and crusting. A single administration of Bravecto chewable tablets or a single application of Bravecto spot-on solution at the currently approved dose is effective in the treatment of sarcoptic mange (caused by Sarcoptes scabiei) in dogs, with elimination of live mite infestation and reduction in clinical signs.
